CDX2 as a Prognostic Biomarker in Stage II and Stage III Colon Cancer.

ABSTRACT: Background The identification of high-risk stage II colon cancers is key to the selection of patients who require adjuvant treatment after surgery. Microarray-based multigene-expression signatures derived from stem cells and progenitor cells hold promise, but they are difficult to use in clinical practice. Methods We used a new bioinformatics approach to search for biomarkers of colon epithelial differentiation across gene-expression arrays and then ranked candidate genes according to the availability of clinical-grade diagnostic assays. With the use of subgroup analysis involving independent and retrospective cohorts of patients with stage II or stage III colon cancer, the top candidate gene was tested for its association with disease-free survival and a benefit from adjuvant chemotherapy

SUBMITTER: Dalerba P 

PROVIDER: S-EPMC4784450 | biostudies-literature | 2016 Jan

REPOSITORIES: biostudies-literature